myHealthbox receives “Collaboration Award” during Innovation Night gala at Cosmofarma

myHealthbox was among the companies awarded on April the 20th during the gala “Innovation Night – Cosmofarma”, at Palazzo de ‘Toschi in Bologna, in the presence of S.E. the Ambassador of Ireland in Italy Colm Ó Floinn. During the night the Adoption Program partnerships between the start-ups and the companies of Cosmofarma StartUp Village have been announced.

We are very pleased to announce that the Francesca Rava Foundation – NPH Italia Onlus has chosen myHealthbox.

myHealthbox is one of the largest search engines for certified information on over 4 million medicines and healthcare products available in over 50 countries, with leaflets in 35 languages. This partnership will allow doctors from the NPH Saint Damien Children’s Hospital in Haiti and the medical staff of NPH Homes in Latin America to use medicines from Italy and abroad in complete safety.

———————————————————————————————————————————-

Tra le start-up premiate il 20 Aprile durante la serata di gala di Innovation Night Cosmofarma, presso Palazzo de’ Toschi a Bologna, alla presenza di S.E. l’Ambasciatore d’Irlanda in Italia Colm Ó Floinn, c’era anche myHealthbox. Attraverso l’Adoption Program sono state annunciate le partnership tra le start-up del Cosmofarma StartUp Village con le aziende e istituzioni dell’Adoption Program.

Siamo lieti di annunciare che la Fondazione Francesca Rava – NPH Italia Onlus ha scelto MyHealthbox, uno dei più grandi motori di ricerca di informazioni certificate su oltre 4 milioni di medicinali e prodotti healthcare disponibili in oltre 50 Paesi, con fogli illustrativi in ben 35 lingue. Questa partnership permetterà ai medici dell’Ospedale pediatrico NPH Saint Damien in Haiti e lo staff sanitario delle Case NPH in America Latina potranno usare in tutta sicurezza i farmaci provenienti dall’Italia e dall’estero.

12 Best Adderall Alternatives: Natural Over the Counter ADHD Substitutes

Adderall. It’s a word that will either make you cringe or make you smile, depending on who you ask. The drug’s intended to be used as a prescription medication to treat ADHD (Attention-Deficit/Hyperactivity Disorder) and narcolepsy. Now, it’s become increasingly popular for its off-label use as a study aid and a quick fix for motivation problems.

Adderall and prescription ADHD medications can be highly dangerous if abused. These stimulants have many adverse side effects and are known to be quite harmful to children despite being FDA approved.

The research team from Cognitune has compiled an article about the best all-natural alternatives to Adderall.

You can read the full article here

EU Moves Towards Inclusion of QR Codes on Pharma Packs

Allowing QR codes on medicines packaging is being considered by European regulators, reflecting the shift towards digital communication between drug makers and patients, according to a recent article in Securing Industry. The move shows that EU regulators are in favor of using on-pack codes in a way that extends beyond compliance with the drug authentication principles – based on 2D datamatrix codes – enshrined within the Falsified Medicines Directive.

The huge increase in smartphone use means more and more companies are using QR codes to interact with customers. For pharmaceuticals, this code would be included on the packaging and link to webpages maintained by drug companies or the National Competent Authorities. The European Medicines Agency (EMA) issued guidance on using QR codes on packs in 2015.

According to a recent position paper, Europe’s Heads of Medicines Agencies’ Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) says the 2D codes that can be scanned by a smartphone could be useful as a means to provide product information for both prescription and over-the-counter medicines.

The group says QR codes are not mandatory but any inclusion of a QR code would be automatically accepted by all Member States “without any further assessment”. The intention of including a QR code would have to be declared in marketing authorization applications, the details of which the CMDh outlines in the position paper.

The CMDh has also agreed that elements that can be provided via a QR code include approved product and statutory information, and risk minimization material such as education material.

But it goes on to say: “The inclusion of the QR code cannot replace the inclusion of the statutory information (printed package leaflet).” Rather the QR code would be a way to provide “updated information” on medicinal products, which may not be included on the printed leaflet.

It also notes that some countries allow the QR code to link to additional information such as video content. The inclusion of such extra information should be managed and discussed nationally.

The position paper only considers the use of QR codes for product information, and stresses that only 2D datamatrix codes can be used for manufacturing processing and as a safety feature under the falsified medicines legislation. The position of the QR code is also discussed in the paper.

Vitamin K2 Impairment by Common Drugs May Cause CVD

Statins and warfarin shown to share mechanism that causes CVD, Diabetes

OSLO, NORGE and METUCHEN, NJ (23 June 2016) A new review paper published in leading journal, Pharmacology, examines the positive associations observed between cardiovascular disease (CVD) and type 2 diabetes mellitus (DM), and the negative effect of medications prescribed to both groups of patients share a common mechanism: to inhibit vitamin K2-dependent processes, which was interpreted to lead to increased onset of CVD, DM, chronic kidney disease, bone fracture, and even mental disorder.

The authors of the review paper1, “Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes,” note that impaired vitamin K2-dependent processes by some types of vegetable oils and medicines, but not plasma high low-density lipoprotein cholesterol, were proposed as the cause of CVD, DM and other lifestyle-related diseases.

“Once again the scientific community recognizes that the inhibition of vitamin K2 synthesis by common medications carries serious, newly recognized repurcussions,” says Hogne Vik, chief medical officer with NattoPharma, the world leader in vitamin K2 research and development, adding that while it has been well known for some time that statins inhibit CoQ10, a 2015 review paper2 finally highlighted that statins also inhibit K2 synthesis. ”Recognized Vitamin K2 antagonists significantly inhibit Vitamin K activity outside the liver with serious, unintended consequences.”

The function of K vitamins is unique among other vitamins and important throughout all life stages. Vitamin K2 activates proteins that are made in different organs in the body – clotting factors in the liver, osteocalcin in bones, and Matrix Gla Protein (MGP) in the vasculature. These proteins help coagulate blood, bind calcium to the surface of bones, and keep calcium from depositing in the arteries and soft tissues.

While the function of Vitamin K2 is vital to ensuring that the body properly utilizes calcium, studies have shown that 97 percent of Western populations are Vitamin K2 deficient/insufficient.3

“We are not only finally seeing recognition that Vitamin K2 is woefully insufficient in the diet, but the is a growing body of evidence that pharmaceuticals further exacerbate the problem of our limited Vitamin K2 status, delivering potentially dangerous consequences for human health,” Vik continues.

# # #

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

References:

1 Okuyama H et al. Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes. Pharmacology 2016;98:134–170. DOI: 10.1159/000446704.

2 Okuyama H et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6.

3 Shea MK et al. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr. 2011 Aug;141(8):152934.

 

myHealthbox al Pharmintech di Bologna

myHealthbox presenterà le sue soluzioni innovative di eLeaflet al Pharmintech di Bologna dal 13 al 15 Aprile 2016.

Tramite il nuovo display interattivo della Corepixx sarà possibile provare dal vivo tutte le nuove funzionalità della nostra offerta eLeaflet.

Vieni a trovarci al Padiglione 22 Stand B88

myHealthbox at Pharmintech, Bologna

myHealthbox will be presenting its eLeaflet solution at Pharmintech in Bologna from the 13th to the 15th of April 2016.

You will be able to try out most of our services live through a new interactive screen provided by Corepixx.

Come meet us at Area 22 Stand B88

myHealthbox presents its multi-language eLeaflet solution at Cosmopack, Bologna

It is now common in our society that different ethnic groups and languages meet and coexist in the same country, in Italy alone there are now more than 5 million people that speak a primary language that is different from Italian (Romanian, Albanian and Arabic are amongst the most spoken). To these language minorities we can then add turists and travellers that live in Italy and speak one of the main European languages (English, Spanish and German are the main ones).

It is easy to see how, when the is a need to read information about the use of medicines of healthcare products (for example the dosage) these people would prefer reading information in their native language which they consider “safer” as less subject to interpretation errors.

Moreover there are in the world dozens of situations where 2 or more official languages are present in the same country (i.e. German in the Alto Adige region in Italy or French and Dutch in Belgium).

In Italy for example there is a requirement, for product sold in the Alto Adige region, for providing patient information in Italian and in German; until recently compliance was achieved by providing two printed versions of the patient information leaflet inside the packaging,today an alternative solution is available by making available a digital versions of the leaflet in German language via web or mobile, these can be also easily printed in the pharmacy upon request.

To provide an answer to these crucial requirement in today’s healthcare communication myHealthbox has extended its eLeaflet product with native support for 35 languages.

The use of myHealthbox as the digital leaflets distribution platform, the data security solutions implemented (both at leaflet and platform level) and the possibility of providing this information also via a QR code printed on the packaging make myHealthbox the solution of choice for those companies that need to satisfy government requirements for selling healthcare product in bi- or multi-lingual regions like Alto Adige in Italy.

To find out more visit us at Cosmopack in Bologna or contact us at sales@myhealthbox.eu

myHealthbox presenta la soluzione eLeaflet con supporto multilingua al Cosmopack di Bologna

Oggi più che mai viviamo in una realtà dove diverse etnie e lingue si incontrano e convivono nello stesso paese, solo in Italia si contano più di 5 milioni di persone che non hanno l’italiano come lingua principale (Romeno, Albanese e Arabo sono le lingue principali) oltre naturalmente a turisti e persone che sono presenti in Italia per lavoro e che parlano una delle altre lingue Europee (Inglese, Spagnolo e tedesco sono le principali).

Si può facilmente capire come, quando si tratta di leggere informazioni sull’uso di medicinali o prodotti per la salute (ad es. la posologia di una farmaco), queste persone preferiscano usare la propria lingua nativa che ritengono istintivamente più “sicura” e meno soggetta ad errori di interpretazione.

Ci sono poi nel mondo decine di realtà dove 2 o più lingue ufficiali coesistono all’interno dello stesso paese (come ad esempio la lingua Tedesca in Alto Adige o Francese ed Olandese in Belgio).

In Italia esiste l’obbligo, per i farmaci venduti in Alto Adige, di fornire le informazioni per il paziente sia in Italiano che in Tedesco; fino a poco tempo fa esistevano 2 versioni cartacee del foglio illustrativo, oggi è possibile utilizzare versioni digitali del foglio in Tedesco disponibili sia tramite web e mobile che stampabili in farmacia su richiesta.

A tutte queste esigenze ha risposto myHealthbox con il suo prodotto eLeaflet che include il supporto nativo per oltre 35 lingue.

La distribuzione dei fogli illustrativi digitali attraverso la piattaforma myHealthbox, le soluzioni di sicurezza dei dati implementate (sia a livello di formato che di piattaforma) e la possibilità di accedere a queste informazioni anche tramite un QR code sulla confezione permettono di ottemperare a tutti i requisiti stabiliti dal Ministero della Salute e da AIFA in termini di soluzioni per il bilinguismo sia specificatamente per la regione Alto Adige che per altre regioni.

Per saperne di più potete venire a visitare in nostro stand al Cosmopack di Bologna o contattarci via email all’indirizzo sales@myhealthbox.eu

myHealthbox al Cosmopack di Bologna

myHealthbox presenterà le sue soluzioni innovative di eLeaflet al Cosmopack di Bologna dal 17 al 20 Marzo 2016.

Tramite il nuovo display interattivo della Coolpix sarà possibile provare dal vivo tutte le nuove funzionalità della nostra offerta eLeaflet.

Vieni a trovarci al Padiglione 20 Stand E30

myHealthbox at Cosmopack, Bologna

myHealthbox will be presenting its eLeaflet solution at Cosmopack in Bologna from the 17th to the 20th of March 2016.

You will be able to try out most of our services live through a new interactive screen provided by Coolpix.

Come meet us at Area 20 Stand E30